Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.790
-0.030 (-1.65%)
At close: Nov 20, 2024, 4:00 PM
1.808
+0.018 (1.01%)
After-hours: Nov 20, 2024, 6:39 PM EST
Akebia Therapeutics Employees
Akebia Therapeutics had 167 employees as of December 31, 2023. The number of employees decreased by 38 or -18.54% compared to the previous year.
Employees
167
Change (1Y)
-38
Growth (1Y)
-18.54%
Revenue / Employee
$1,017,240
Profits / Employee
-$275,401
Market Cap
390.54M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Sonida Senior Living | 3,955 |
Canopy Growth | 1,029 |
Revance Therapeutics | 597 |
Alector | 244 |
Prime Medicine | 234 |
KalVista Pharmaceuticals | 150 |
4D Molecular Therapeutics | 147 |
Larimar Therapeutics | 42 |
AKBA News
- 15 hours ago - Q3 2024 Earnings: Hold Akebia Therapeutics - Seeking Alpha
- 6 days ago - Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease - PRNewsWire
- 8 days ago - Akebia Therapeutics to Present at the Jefferies London Healthcare Conference - PRNewsWire
- 13 days ago - Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - PRNewsWire
- 19 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 19 days ago - Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights - PRNewsWire
- 4 weeks ago - Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - PRNewsWire